(Q33400687)

English

Phase I dose-escalation study to examine the safety and tolerability of LY2603618, a checkpoint 1 kinase inhibitor, administered 1 day after pemetrexed 500 mg/m(2) every 21 days in patients with cancer

scientific article

In more languages

default for all languages

No label defined

No description defined

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

26 July 2017

Phase I dose-escalation study to examine the safety and tolerability of LY2603618, a checkpoint 1 kinase inhibitor, administered 1 day after pemetrexed 500 mg/m(2) every 21 days in patients with cancer (English)

1 reference

Europe PubMed Central

PubMed publication ID

26 July 2017

author name string

Glen J Weiss

1

1 reference

Europe PubMed Central

PubMed publication ID

26 July 2017

Ross C Donehower

2

1 reference

Europe PubMed Central

PubMed publication ID

26 July 2017

Tara Iyengar

3

1 reference

Europe PubMed Central

PubMed publication ID

26 July 2017

Ramesh K Ramanathan

4

1 reference

Europe PubMed Central

PubMed publication ID

26 July 2017

Karen Lewandowski

5

1 reference

Europe PubMed Central

PubMed publication ID

26 July 2017

Eric Westin

6

1 reference

Europe PubMed Central

PubMed publication ID

26 July 2017

Karla Hurt

7

1 reference

Europe PubMed Central

PubMed publication ID

26 July 2017

Scott M Hynes

8

1 reference

Europe PubMed Central

PubMed publication ID

26 July 2017

Stephen P Anthony

9

1 reference

Europe PubMed Central

PubMed publication ID

26 July 2017

Scott McKane

10

1 reference

Europe PubMed Central

PubMed publication ID

26 July 2017

publication date

11 April 2012

1 reference

Europe PubMed Central

PubMed publication ID

26 July 2017

Investigational New Drugs

1 reference

Europe PubMed Central

PubMed publication ID

26 July 2017

31

1 reference

Europe PubMed Central

PubMed publication ID

26 July 2017

1

1 reference

Europe PubMed Central

PubMed publication ID

26 July 2017

136-144

1 reference

Europe PubMed Central

PubMed publication ID

26 July 2017

New insights into checkpoint kinase 1 in the DNA damage response signaling network

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3715080

21 June 2018

Chk1 haploinsufficiency results in anemia and defective erythropoiesis

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3715080

21 June 2018

Targeting the checkpoint kinase Chk1 in cancer therapy

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3715080

21 June 2018

A phase I trial of UCN-01 and prednisone in patients with refractory solid tumors and lymphomas

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3715080

21 June 2018

Pharmacological aspects of the enzastaurin-pemetrexed combination in non-small cell lung cancer (NSCLC).

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3715080

21 June 2018

Targeting checkpoint kinase 1 in cancer therapeutics

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3715080

21 June 2018

Pemetrexed: a multitargeted antifolate

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3715080

21 June 2018

Gemcitabine-induced activation of checkpoint signaling pathways that affect tumor cell survival.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3715080

21 June 2018

Role of checkpoint kinase 1 in preventing premature mitosis in response to gemcitabine

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3715080

21 June 2018

Disruption of the checkpoint kinase 1/cell division cycle 25A pathway abrogates ionizing radiation-induced S and G2 checkpoints

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3715080

21 June 2018

Chk1 is an essential kinase that is regulated by Atr and required for the G(2)/M DNA damage checkpoint

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3715080

21 June 2018

Downstream molecular determinants of response to 5-fluorouracil and antifolate thymidylate synthase inhibitors.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3715080

21 June 2018

Phase II study of the multitargeted antifolate LY231514 (ALIMTA, MTA, pemetrexed disodium) in patients with advanced pancreatic cancer

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3715080

21 June 2018

Conservation of the Chk1 checkpoint pathway in mammals: linkage of DNA damage to Cdk regulation through Cdc25

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3715080

21 June 2018

Cell cycle effects of antifolate antimetabolites: implications for cytotoxicity and cytostasis

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3715080

21 June 2018

Phase Ib safety and pharmacokinetic evaluation of daily and twice daily oral enzastaurin in combination with pemetrexed in advanced/metastatic cancer.

1 reference

https://api.crossref.org/works/10.1007%2FS10637-012-9815-9

21 January 2018

A randomized phase III trial comparing standard and high-dose pemetrexed as second-line treatment in patients with locally advanced or metastatic non-small-cell lung cancer

1 reference

https://api.crossref.org/works/10.1007%2FS10637-012-9815-9

21 January 2018

FDA drug approval summary: pemetrexed for injection (Alimta) for the treatment of non-small cell lung cancer

1 reference

https://api.crossref.org/works/10.1007%2FS10637-012-9815-9

21 January 2018

Cell cycle modulation by a multitargeted antifolate, LY231514, increases the cytotoxicity and antitumor activity of gemcitabine in HT29 colon carcinoma

1 reference

https://pubmed.ncbi.nlm.nih.gov/22492020

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Identifiers

10.1007/S10637-012-9815-9

1 reference

Europe PubMed Central

PubMed publication ID

26 July 2017

Dimensions Publication ID

0 references

PMC publication ID

1 reference

Europe PubMed Central

PubMed publication ID

26 July 2017

PubMed publication ID

1 reference

Europe PubMed Central

PubMed publication ID

26 July 2017

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q33400687&oldid=2195324603"